A citation-based method for searching scientific literature

Rui Batista, Luís Lima, João Vinagre, Vasco Pinto, Joana Lyra, Valdemar Máximo, Lúcio Santos, Paula Soares. Int J Mol Sci 2020
Times Cited: 13







List of co-cited articles
48 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Combined genetic and epigenetic alterations of the TERT promoter affect clinical and biological behavior of bladder cancer.
Ricardo Leão, Donghyun Lee, Arnaldo Figueiredo, Thomas Hermanns, Peter Wild, Martin Komosa, Irene Lau, Mathew Mistry, Nuno Miguel Nunes, Aryeh J Price,[...]. Int J Cancer 2019
21
38

TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism.
P Sivaramakrishna Rachakonda, Ismail Hosen, Petra J de Verdier, Mahdi Fallah, Barbara Heidenreich, Charlotta Ryk, N Peter Wiklund, Gunnar Steineck, Dirk Schadendorf, Kari Hemminki,[...]. Proc Natl Acad Sci U S A 2013
209
38

Frequency of TERT promoter mutations in human cancers.
João Vinagre, Ana Almeida, Helena Pópulo, Rui Batista, Joana Lyra, Vasco Pinto, Ricardo Coelho, Ricardo Celestino, Hugo Prazeres, Luis Lima,[...]. Nat Commun 2013
512
23

Understanding TERT Promoter Mutations: A Common Path to Immortality.
Robert J A Bell, H Tomas Rube, Ana Xavier-Magalhães, Bruno M Costa, Andrew Mancini, Jun S Song, Joseph F Costello. Mol Cancer Res 2016
114
23

TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal.
Patrick J Killela, Zachary J Reitman, Yuchen Jiao, Chetan Bettegowda, Nishant Agrawal, Luis A Diaz, Allan H Friedman, Henry Friedman, Gary L Gallia, Beppino C Giovanella,[...]. Proc Natl Acad Sci U S A 2013
848
23

Risk Stratification Tools and Prognostic Models in Non-muscle-invasive Bladder Cancer: A Critical Assessment from the European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel.
Viktor Soukup, Otakar Čapoun, Daniel Cohen, Virginia Hernández, Maximilian Burger, Eva Compérat, Paolo Gontero, Thomas Lam, A Hugh Mostafid, Joan Palou,[...]. Eur Urol Focus 2020
31
23

Atezolizumab: A PD-L1-Blocking Antibody for Bladder Cancer.
Brant A Inman, Thomas A Longo, Sundhar Ramalingam, Michael R Harrison. Clin Cancer Res 2017
78
15

Cancer stem cells as a therapeutic target in bladder cancer.
Nazi Aghaalikhani, Nadereh Rashtchizadeh, Pejman Shadpour, Abdolamir Allameh, Marzieh Mahmoodi. J Cell Physiol 2019
21
15

Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer.
Claire Biot, Cyrill A Rentsch, Joel R Gsponer, Frédéric D Birkhäuser, Hélène Jusforgues-Saklani, Fabrice Lemaître, Charlotte Auriau, Alexander Bachmann, Philippe Bousso, Caroline Demangel,[...]. Sci Transl Med 2012
134
15

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
Jonathan E Rosenberg, Jean Hoffman-Censits, Tom Powles, Michiel S van der Heijden, Arjun V Balar, Andrea Necchi, Nancy Dawson, Peter H O'Donnell, Ani Balmanoukian, Yohann Loriot,[...]. Lancet 2016
15

Immunological mechanisms of intravesical chitosan/interleukin-12 immunotherapy against murine bladder cancer.
Sean G Smith, John L Baltz, Bhanu Prasanth Koppolu, Sruthi Ravindranathan, Khue Nguyen, David A Zaharoff. Oncoimmunology 2016
16
15

Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches.
Dongkui Song, Thomas Powles, Lei Shi, Lirong Zhang, Molly A Ingersoll, Yong-Jie Lu. J Pathol 2019
18
15

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.
Joaquim Bellmunt, Ronald de Wit, David J Vaughn, Yves Fradet, Jae-Lyun Lee, Lawrence Fong, Nicholas J Vogelzang, Miguel A Climent, Daniel P Petrylak, Toni K Choueiri,[...]. N Engl J Med 2017
15

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.
Padmanee Sharma, Margitta Retz, Arlene Siefker-Radtke, Ari Baron, Andrea Necchi, Jens Bedke, Elizabeth R Plimack, Daniel Vaena, Marc-Oliver Grimm, Sergio Bracarda,[...]. Lancet Oncol 2017
768
15

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study.
Thomas Powles, Peter H O'Donnell, Christophe Massard, Hendrik-Tobias Arkenau, Terence W Friedlander, Christopher J Hoimes, Jae Lyun Lee, Michael Ong, Srikala S Sridhar, Nicholas J Vogelzang,[...]. JAMA Oncol 2017
473
15

The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy.
Jonathan J Havel, Diego Chowell, Timothy A Chan. Nat Rev Cancer 2019
676
15

Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccine.
Koji Kawai, Jun Miyazaki, Akira Joraku, Hiroyuki Nishiyama, Hideyuki Akaza. Cancer Sci 2013
96
15

Sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomized prospective trial.
Eduardo Solsona, Rosario Madero, Venancio Chantada, Jesus M Fernandez, Juan A Zabala, José A Portillo, Jose M Alonso, Ander Astobieta, Miguel Unda, Luis Martinez-Piñeiro,[...]. Eur Urol 2015
36
15


TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas.
Miguel Melo, Adriana Gaspar da Rocha, João Vinagre, Rui Batista, Joana Peixoto, Catarina Tavares, Ricardo Celestino, Ana Almeida, Catarina Salgado, Catarina Eloy,[...]. J Clin Endocrinol Metab 2014
299
15

Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.
Jianjiong Gao, Bülent Arman Aksoy, Ugur Dogrusoz, Gideon Dresdner, Benjamin Gross, S Onur Sumer, Yichao Sun, Anders Jacobsen, Rileen Sinha, Erik Larsson,[...]. Sci Signal 2013
15

Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT.
S L Weinrich, R Pruzan, L Ma, M Ouellette, V M Tesmer, S E Holt, A G Bodnar, S Lichtsteiner, N W Kim, J B Trager,[...]. Nat Genet 1997
780
15

TERT Promoter Mutations are Associated with Visceral Spreading in Melanoma of the Trunk.
Simona Osella-Abate, Luca Bertero, Rebecca Senetta, Sara Mariani, Francesco Lisa, Vittoria Coppola, Jasna Metovic, Barbara Pasini, Susana Puig S, Maria Teresa Fierro,[...]. Cancers (Basel) 2019
8
25

TERT promoter mutations and telomeres during tumorigenesis.
Franziska K Lorbeer, Dirk Hockemeyer. Curr Opin Genet Dev 2020
14
15

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.
Ahmet Zehir, Ryma Benayed, Ronak H Shah, Aijazuddin Syed, Sumit Middha, Hyunjae R Kim, Preethi Srinivasan, Jianjiong Gao, Debyani Chakravarty, Sean M Devlin,[...]. Nat Med 2017
15

TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas.
Matthias Simon, Ismail Hosen, Konstantinos Gousias, Sivaramakrishna Rachakonda, Barbara Heidenreich, Marco Gessi, Johannes Schramm, Kari Hemminki, Andreas Waha, Rajiv Kumar. Neuro Oncol 2015
103
15

Tumor mutational load predicts survival after immunotherapy across multiple cancer types.
Robert M Samstein, Chung-Han Lee, Alexander N Shoushtari, Matthew D Hellmann, Ronglai Shen, Yelena Y Janjigian, David A Barron, Ahmet Zehir, Emmet J Jordan, Antonio Omuro,[...]. Nat Genet 2019
898
15

Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma.
Xiaoli Liu, Guojun Wu, Yuan Shan, Christian Hartmann, Andreas von Deimling, Mingzhao Xing. Cell Cycle 2013
95
15

New therapies in nonmuscle invasive bladder cancer treatment.
Kareem N Rayn, Graham R Hale, Gustavo Pena-La Grave, Piyush K Agarwal. Indian J Urol 2018
15
15


Bladder cancer.
Ashish M Kamat, Noah M Hahn, Jason A Efstathiou, Seth P Lerner, Per-Uno Malmström, Woonyoung Choi, Charles C Guo, Yair Lotan, Wassim Kassouf. Lancet 2016
497
15

A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157.
Noah M Hahn, Trinity J Bivalacqua, Ashley E Ross, George J Netto, Alex Baras, Jong Chul Park, Carolyn Chapman, Timothy A Masterson, Michael O Koch, Richard Bihrle,[...]. Clin Cancer Res 2017
34
15

Positive fibroblast growth factor receptor 3 immunoreactivity is associated with low-grade non-invasive urothelial bladder cancer.
Cédric Poyet, Thomas Hermanns, Qing Zhong, Eva Drescher, Daniel Eberli, Maximilian Burger, Ferdinand Hofstaedter, Arndt Hartmann, Robert Stöhr, Ellen C Zwarthoff,[...]. Oncol Lett 2015
7
28

Copy number analysis of 24 oncogenes: MDM4 identified as a putative marker for low recurrence risk in non muscle invasive bladder cancer.
Samanta Salvi, Daniele Calistri, Giorgia Gurioli, Elisa Carretta, Luigi Serra, Roberta Gunelli, Wainer Zoli, Valentina Casadio. Int J Mol Sci 2014
10
20

Prognostic Effect of FGFR Mutations or Gene Fusions in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Results from a Large, Single-institution Cohort.
Andrea Necchi, Salvatore Lo Vullo, Daniele Raggi, Annunziata Gloghini, Patrizia Giannatempo, Maurizio Colecchia, Luigi Mariani. Eur Urol Focus 2019
5
40


Immunotherapy for the Treatment of Urothelial Carcinoma.
Nicholas M Donin, Andrew T Lenis, Stuart Holden, Alexandra Drakaki, Allan Pantuck, Arie Belldegrun, Karim Chamie. J Urol 2017
57
15

TERT C228T mutation in non-malignant bladder urothelium is associated with intravesical recurrence for patients with non-muscle invasive bladder cancer.
Yujiro Hayashi, Kazutoshi Fujita, Satoshi Nojima, Eisuke Tomiyama, Makoto Matsushita, Yoko Koh, Kosuke Nakano, Cong Wang, Yu Ishizuya, Taigo Kato,[...]. Mol Oncol 2020
8
25

Implications of TERT promoter mutations and telomerase activity in urothelial carcinogenesis.
Cagatay Günes, Felix Wezel, Jennifer Southgate, Christian Bolenz. Nat Rev Urol 2018
23
15

Mutations in TERT promoter and FGFR3 and telomere length in bladder cancer.
Ismail Hosen, P Sivaramakrishna Rachakonda, Barbara Heidenreich, Petra J de Verdier, Charlotta Ryk, Gunnar Steineck, Kari Hemminki, Rajiv Kumar. Int J Cancer 2015
56
15

Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.
Yohann Loriot, Andrea Necchi, Se Hoon Park, Jesus Garcia-Donas, Robert Huddart, Earle Burgess, Mark Fleming, Arash Rezazadeh, Begoña Mellado, Sergey Varlamov,[...]. N Engl J Med 2019
296
15

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.
Alessandro Liberati, Douglas G Altman, Jennifer Tetzlaff, Cynthia Mulrow, Peter C Gøtzsche, John P A Ioannidis, Mike Clarke, P J Devereaux, Jos Kleijnen, David Moher. PLoS Med 2009
15

Promoter region mutations of the telomerase reverse transcriptase (TERT) gene in head and neck squamous cell carcinoma.
Ismail Yilmaz, Bulent Evren Erkul, Sule Ozturk Sari, Gizem Issin, Ersin Tural, Neslihan Terzi Kaya Terzi, Huseyin Karatay, Mehmet Celik, Murat Ulusan, Bilge Bilgic. Oral Surg Oral Med Oral Pathol Oral Radiol 2020
3
66

Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
Yves Allory, Willemien Beukers, Ana Sagrera, Marta Flández, Miriam Marqués, Mirari Márquez, Kirstin A van der Keur, Lars Dyrskjot, Irene Lurkin, Marcel Vermeij,[...]. Eur Urol 2014
156
15

Detection of multiple mutations in urinary exfoliated cells from male bladder cancer patients at diagnosis and during follow-up.
Rossana Critelli, Francesca Fasanelli, Marco Oderda, Silvia Polidoro, Manuela Bianca Assumma, Clara Viberti, Mirko Preto, Paolo Gontero, Giuseppina Cucchiarale, Irene Lurkin,[...]. Oncotarget 2016
29
15

Prognostic Value of TERT Alterations, Mutational and Copy Number Alterations Burden in Urothelial Carcinoma.
Sumit Isharwal, François Audenet, Esther Drill, Eugene J Pietzak, Gopa Iyer, Irina Ostrovnaya, Eugene Cha, Timothy Donahue, Maria Arcila, Gowtham Jayakumaran,[...]. Eur Urol Focus 2019
16
15

Cancer. TERT promoter mutations and telomerase reactivation in urothelial cancer.
Sumit Borah, Linghe Xi, Arthur J Zaug, Natasha M Powell, Garrett M Dancik, Scott B Cohen, James C Costello, Dan Theodorescu, Thomas R Cech. Science 2015
190
15

Telomerase reverse transcriptase gene promoter mutations help discern the origin of urogenital tumors: a genomic and molecular study.
Song Wu, Peide Huang, Chong Li, Yi Huang, Xianxin Li, Yongqiang Wang, Chao Chen, Zhaojie Lv, Aifa Tang, Xiaojuan Sun,[...]. Eur Urol 2014
65
15

mTOR inhibitors in urinary bladder cancer.
R Pinto-Leite, R Arantes-Rodrigues, Nuno Sousa, P A Oliveira, L Santos. Tumour Biol 2016
19
7

The Antitumor Effect of Curcumin in Urothelial Cancer Cells Is Enhanced by Light Exposure In Vitro.
Frederik Roos, Katherina Binder, Jochen Rutz, Sebastian Maxeiner, August Bernd, Stefan Kippenberger, Nadja Zöller, Felix K-H Chun, Eva Juengel, Roman A Blaheta. Evid Based Complement Alternat Med 2019
5
20


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.